Status: Not yet recruiting
Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)
The purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.
Participants needed: 14
Trial details
Phase: Phase 1, Phase 2Age: 20-80Biological sex: AllType: InterventionalSponsor: Heartseed Inc.Updated: Jan 16, 2026
Eligibility criteria
Patients with resting left ventricular ejection fraction (LVEF) ≦40% based on in... [+2]
Patients with cardiac devices such as pacemakers, implantable cardioverter defib... [+2]